Obeticholic acid-a new therapy in PBC and NASH
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Introduction: Obeticholic acid (OCA) is a semi-synthetic hydrophobic bile acid (BA) analogue that is highly selective agonist of farnesoid X receptor (FXR), a key nuclear BA receptor, which induces expression of gut-derived hormones, in particular fibroblast growth factor 19. The resulting beneficial effects of OCA on glucose and lipid metabolism and particularly hepatic inflammation make it a candidate for the treatment of a variety of conditions including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Sources of data: In PBC patients who have not initially responded to ursodeoxycholic acid, OCA has been shown in double-blind controlled clinical trials to significantly reduce serum alkaline phosphatase. To date, OCA is the only therapy licensed by the FDA, EMA and endorsed by NICE as second line therapy for PBC. No medications are currently approved in Europe or the USA for the treatment of NASH. In recent clinical trials, OCA has been shown encouraging results by improving liver blood tests and reducing liver fibrosis with no worsening of NASH. Areas of agreement: OCA is the established second line therapy for PBC in those patients who fail to adequately respond to ursodeoxycholic acid. Areas of controversy: The main side effects of OCA treatment in both PBC and NASH is that of dose-dependent pruritis which can lead to treatment discontinuation in ~1–10% of patients. In addition, OCA-treated patients may also exhibit (reversible) alterations in serum lipid levels; most notably a small decrease in high density lipoprotein cholesterol. It is not yet known whether these changes carry a long-term cardiovascular risk in NASH. In addition, the relatively high cost of OCA may limit its use in cash-limited health systems. Growing Points: Additional clinical trials are in progress to ascertain the long-term effects of OCA on survival in PBC and NASH. Areas timely for developing research: New FXR agonists with a lower rate of side effects are being developed and trialed. Combination therapy with other agents may offer increased efficacy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FXR, a nuclear bile acid receptor, plays a central role in regulating bile acid homeostasis and stimulates the secretion of gut-derived hormones, particularly fibroblast growth factor 19 [26,27].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [26]
Citations
Cites
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Cited by
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
Sun, L., Cai, J., & Gonzalez, F. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00404-2 · Cited by 435
Kuang, J., Wang, J., Li, Y., Li, M., Zhao, M., Ge, K., Zheng, D., Cheung, K. C. P., Liao, B., Wang, S., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.011 · Cited by 321
Thibaut, R., Gage, M. C., Pineda‐Torra, I., Chabrier, G., Venteclef, N., & Alzaid, F. (2022) · The FEBS Journal · doi:10.1111/febs.15877 · Cited by 95
ASBT(SLC10A2): A promising target for treatment of diseases and drug discovery
Yang, N., Dong, Y., Jia, G., Fan, S., Li, S.-Z., Yang, S., & Li, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110835 · Cited by 87
Baghaei, K., Mazhari, S., Tokhanbigli, S., Parsamanesh, G., Alavifard, H., Schaafsma, D., & Ghavami, S. (2021) · World Journal of Gastroenterology · doi:10.1016/j.drudis.2021.12.012 · Cited by 93
Wang, M., Zhang, K.-H., Liu, F., Zhou, R., Zeng, Y., Chen, A., Yu, Y., Xia, Q., Zhu, C., & Lin, C. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155124 · Cited by 84
Ciaula, A. D., Bonfrate, L., Baj, J., Khalil, M., Garruti, G., Stellaard, F., Wang, H. H., Wang, D. Q. ‐., & Portincasa, P. (2022) · Nutrients · doi:10.3390/nu14234950 · Cited by 80
Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply
Du, K., Li, S., Li, C., Li, P., Miao, C., Luo, T., Qiu, B., & Ding, W. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.07.013 · Cited by 69
Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
Sharma, M., Premkumar, M., Kulkarni, A. V., Kumar, P., Reddy, D. N., & Rao, N. P. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00055 · Cited by 61
Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases
Almeqdadi, M., & Gordon, F. D. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.013 · Cited by 55
State-of-the-art liver disease research using liver-on-a-chip
Deguchi, S., & Takayama, K. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00248-0 · Cited by 46
Mitochondrial and metabolic dysfunction of peripheral immune cells in multiple sclerosis
Wang, P., Jiang, F., Zeng, Q., Yin, W., Hu, Y.-Z., Li, Q., & Hu, Z. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03016-8 · Cited by 55
“Obeticholic acid (OCA) is a unique medication that regulates various metabolic processes, including cholesterol production, glucose metabolism, inflammation, and apoptosis [110].”
BackgroundShi, T., Malik, A., Yang vom Hofe, A., Matuschek, L., Mullen, M., Lages, C. S., Kudira, R., Singh, R., Zhang, W., Setchell, K. D. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi4354 · Cited by 46
“Food and Drug Administration–approved therapy for primary biliary cholangitis (PBC), raised concerns about drug accumulation causing pruritus and hepatic decompensation in patients with cirrhosis (14).”
BackgroundJiang, M., Huang, C., Wu, Q., Su, Y. J., Wang, X., Xuan, Z., Wang, Y., Xu, F., & Ge, C. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115965 · Cited by 51
The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
Rausch, M., Samodelov, S. L., Visentin, M., & Kullak-Ublick, G. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213967 · Cited by 47
Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease
Xiao, Y., Kim, M., & Lazar, M. A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101119 · Cited by 43
“The FXR agonist obeticholic acid was approved by the FDA for biliary cholangitis therapy, but the recent outcome of a clinical trial for NASH resolution was disappointing [6,174].”
BackgroundObeticholic Acid for Primary Biliary Cholangitis
Floreani, A., Gabbia, D., & De Martin, S. (2022) · Biomedicines · doi:10.3390/biomedicines10102464 · Cited by 41
“As a consequence of the alteration of lipid metabolism, which is due to other molecular signaling pathways triggered by FXR activation, an increase in total serum lipid levels and a small decrease in high-density lipoprotein (HDL) have also been reported in PBC patients treated with OCA, but to date these effects have…”
BackgroundNovel targets for mucosal healing in inflammatory bowel disease therapy
Mansouri, P., Mansouri, P., Behmard, E., Najafipour, S., Kouhpayeh, A., & Farjadfar, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113544 · Cited by 43
Azizsoltani, A., Hatami, B., Zali, M. R., Mahdavi, V., Baghaei, K., & Alizadeh, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115777 · Cited by 40
Bile Acids and Bilirubin Role in Oxidative Stress and Inflammation in Cardiovascular Diseases
Punzo, A., Silla, A., Fogacci, F., Perillo, M., Cicero, A. F. G., & Caliceti, C. (2024) · Diseases · doi:10.3390/diseases12050103 · Cited by 44
“On the other side, obeticholic acid (OCA), which is a semi-synthetic BA analog (a highly selective agonist of FXR), is associated with a mild but significant reduction in HDL-C and apolipoprotein A-1 [87].”
BackgroundBurnout Syndrome during Residency Training in Jordan: Prevalence, Risk Factors, and Implications
Nimer, A., Naser, S., Sultan, N. G., Alasad, R. S., Rabadi, A. D., Abu-Jubba, M., Al-Sabbagh, M. Q., Jaradat, K. M., Alkayed, Z., Aborajooh, E. A., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18041557 · Cited by 40
“Introduction The concept of burnout was introduced independently by Maslach and Freudenberger in the mid-1970s [1] and defined as a syndrome of physical, mental, and emotional exhaustion that arises in response to continuous stress [2].”
BackgroundTherapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC
Boslem, E., Reibe, S., Carlessi, R., Smeuninx, B., Tegegne, S., Egan, C. L., McLennan, E., Terry, L. V., Nobis, M., Mu, A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh0831 · Cited by 39
“For example,MK-4074, a liver-specific ACC1/2 inhibitor, or the FXR ligand obeticholic acid is quite effective in ameliorating liver fat but unfortunately markedly increases either plasma triglycerides or cholesterol (9, 10).”
BackgroundGut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions
Zhao, Q., Wu, J., Ding, Y., Pang, Y., & Jiang, C. (2023) · Life Metabolism · doi:10.1093/lifemeta/load032 · Cited by 35
Luo, Z., Zhou, W., Xie, T., Xu, W., Shi, C., Xiao, Z., Si, Y., Ma, Y., Ren, Q., Di, L., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.027 · Cited by 33
Nie, Y., Zhou, W., Niu, T., Mao, M., Zhan, Y., Li, Y., Wang, K., Li, M., & Ding, K. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01454-x · Cited by 31
“Although belapectin [7], selonsertib [8], obeticholic acid (OCA) [9 – 12], and other candidate drugs have been evaluated under clinical trials for liver diseases with fi brosis, they either fail to ameliorate fi brosis or have relatively serious side effects.”
The Gut‒Liver Axis in Liver Disease: Molecular Mechanisms and Therapeutic Targets
Chen, Z., Liao, S., Wu, S., Chen, S., Tang, Q., Zhou, L., Li, X., Hu, H., Xu, J., Zhang, A., et al. (2025) · MedComm · doi:10.1002/mco2.70458 · Cited by 34
Liu, Y., Huang, K., Zhang, Y., Cao, H., & Guan, X. (2023) · Food & Function · doi:10.1039/d3fo02471g · Cited by 26
Chen, Z., Liu, S., He, C., Sun, J., Wang, L., Chen, H., & Zhang, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.578548 · Cited by 25
“The therapeutic approaches for PBC remain limited: ursodeoxycholic acid (UDCA) and obeticholic acid (Ocaliva) are the only FDA-approved agents, with ∼60% biochemical response to UDCA (1, 5).”
BackgroundReview of current and new drugs for the treatment of metabolic-associated fatty liver disease
Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 25
“FGF-19 plays a significant role in hepatic inflammation and is essential in treating MAFLD [96].”
Lei, N., Song, H., Zeng, L., Ji, S., Meng, X., Zhu, X., Li, X., Feng, Q., Liu, J., & Mu, J. (2023) · Molecules · doi:10.3390/molecules28073185 · Cited by 21
“Lastly, FXR agonists obeticholic acid and EDP-305 may cause pruritus [34,35].”
BackgroundThe emerging significance of mitochondrial targeted strategies in NAFLD treatment
Zhang, T., Nie, Y., & Wang, J. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121943 · Cited by 23
Li, Z., Deng, L., Cheng, M., Ye, X., Yang, N., Fan, Z., & Sun, L. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5730 · Cited by 22
“OCA, a potent synthetic FXR agonist, has been approved by the US Food and Drug Administration to treat primary biliary cholangitis (157).”
Wen, Y., Zou, Z.-Y., Zhao, G., Zhang, M., Zhang, Y., Wang, G., Shi, J., Wang, Y.-Y., Song, Y.-Y., Wang, H., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01329-1 · Cited by 20
“However, due to the side effects, including pruritus and elevated LDL cholesterol levels, the FDA did not approve OCA for this indication [18 – 21].”
Advances in the treatment of liver injury based on mesenchymal stem cell-derived exosomes
Hu, C., & Wang, L. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04087-3 · Cited by 22
Non-coding RNA crosstalk with nuclear receptors in liver disease
Wu, J., Nagy, L. E., Liangpunsakul, S., & Wang, L. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166083 · Cited by 22
“Obeticholic acid (OCALIVA ® ), the first farnesoid X receptor (FXR) agonist, approved for the treatment of primary biliary cholangitis (PBC), is undergoing development for the treatment of several liver diseases and related disorders [9, 10].”
BackgroundSun, L. Y., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01052-3 · Cited by 19
“OCA, a synthetic farnesoid X receptor (FXR) agonist that inhibits the synthesis of endogenous BAs, has been approved by the FDA for the treatment of primary biliary cholangitis [50].”
BackgroundMacrophages in cholangiopathies
Bruneau, A., Guillot, A., & Tacke, F. (2022) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000814 · Cited by 18
Jang, H.-J., Han, N., Staatz, C. E., Kwak, J., & Baek, I. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102227 · Cited by 17
Chen, C., Zhang, B., Tu, J., Peng, Y., Zhou, Y., Yang, X., Yu, Q.-M., & Tan, X. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115992 · Cited by 18
Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
Lin, C., Yu, B., Chen, L., Zhang, Z., Ye, W., Zhong, H., Bai, W., Yang, Y., & Nie, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.880508 · Cited by 24
Cytochrome P450 Omega-Hydroxylase 4a14 Attenuates Cholestatic Liver Fibrosis
Li, S., Wang, C., Zhang, X., & Su, W. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.688259 · Cited by 16
“The discrepancy of Cyp4a14 in NASH and PBC animal model is very similar to FXR. FXR activation by OCA or GW4064 increased expression of Pparα, Cpt1α, and Cyp4a14 in HFD mice (Gai et al., 2016).”
BackgroundInfluentialRepurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
Jose, S., Devi, S. S., Sajeev, A., Girisa, S., Alqahtani, M. S., Abbas, M., Alshammari, A., Sethi, G., & Kunnumakkara, A. B. (2022) · Bioscience Reports · doi:10.1042/bsr20212791 · Cited by 15
Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse
Lin, C., Yu, B., Liu, X., Chen, L., Zhang, Z., Ye, W., Zhong, H., Bai, W., Yang, Y., & Nie, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112984 · Cited by 15
Ahmed, N. R., Kulkarni, V. V., Pokhrel, S., Akram, H., Abdelgadir, A., Chatterjee, A., & Khan, S. (2022) · Cureus · doi:10.7759/cureus.24829 · Cited by 15
“OCA is a semi-synthetic, modified bile acid derived from chenodeoxycholic acid [23].”
The treatment of primary biliary cholangitis: from shadow to light
Dražilová, S., Koky, T., Macej, M., Janíčko, M., Simkova, D., & Jarčuška, P. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241265782 · Cited by 16
Zhao, X., Li, R., Sun, R., Pan, Q., Lu, H., & Chai, J. (2025) · EngMedicine · doi:10.1016/j.engmed.2025.100088 · Cited by 14
Meshanni, J. A., Lee, J. M., Vayas, K. N., Sun, R., Jiang, C., Guo, G. L., Gow, A. J., Laskin, J. D., & Laskin, D. L. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001557 · Cited by 12
Yang, Y., Yuan, W., He, K., Lin, C., Du, S., Kou, Y., & Nie, B. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1366479 · Cited by 13
Obeticholic acid attenuates the intestinal barrier disruption in a rat model of short bowel syndrome
Hou, L., Wang, H., Yan, M., Cai, Y., Zheng, R., Ma, Y., Tang, W., & Jiang, W. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167221 · Cited by 11
Yang, R., Yang, H., Huili, Y. A. N. G., Jiang, D., Xu, L., & Feng, L. (2022) · PeerJ · doi:10.7717/peerj.14171 · Cited by 12
A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection
Batiha, G. E., Al-Kuraishy, H. M., Al-Gareeb, A. I., Youssef, F. S., El-Sherbeni, S. A., & Negm, W. A. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01111-x · Cited by 11
“Intercept Pharmaceuticals nowadays develops Ocaliva™, a FXR agonist, to manage different liver diseases (Chapman and Lynch 2020).”
BackgroundInfluentialCharacterization of diseased primary human hepatocytes in an all-human cell-based triculture system
Odanga, J. J., Anderson, S. M., Breathwaite, E. K., Presnell, S. C., LeCluyse, E. L., Chen, J., & Weaver, J. R. (2024) · Scientific Reports · doi:10.1038/s41598-024-57463-7 · Cited by 11
Hai, L., Wu, J., Pan, X., Yin, W., & Wu, Z. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70084 · Cited by 11
Gao, Y., Li, L., Li, B., & Zhan, Y. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/8829510 · Cited by 11
“Recent clinical trials showed that OCA could affect lipid profiles of the average population [29] and might have a beneficial impact on metabolic syndrome [30, 31].”
Liu, S., Yang, S., Blažeković, B., Lu, L., Zhang, J., & Wang, Y. N. (2024) · Engineering · doi:10.1016/j.eng.2023.11.017 · Cited by 10
Mitochondrial targeted therapies in MAFLD
Lai, S., Tang, D., & Feng, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151498 · Cited by 11
You, L., Wang, K., Lin, J., Ren, X.-Y., Wei, Y., Li, W.-X., Gao, Y., Kong, X., & Sun, X. (2022) · Gene · doi:10.1016/j.gene.2022.146973 · Cited by 10
Obeticholic Acid—A Pharmacological and Clinical Review
Keshvani, C., Kopel, J. J., & Goyal, H. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3010017 · Cited by 12
“This molecule can act as an endocrine signaling hormone, activating the JNK signaling cascade, and causing a downregulation of CYP7A1 expression after reaching the liver via enterohepatic circulation [14,15].”
BackgroundLi, Z., Chen, S., Yin, B., Wei, J., Wang, D., Zhou, H., & Sun, Z. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00904-5 · Cited by 8
“…our study found that IF intervention resulted in a reduction in the levels of obeticholic acid, a semi-synthetic hydrophobic bile acid (BA) analogue that is highly selective agonist of farne-soid X receptor (FXR), a key nuclear BA receptor, which induces expression of gut-derived hormones [41].”
Kakde, S. P., Mushtaq, M., Liaqat, M., Ali, H., Mushtaq, M. M., Sarwer, M. A., Ullah, S., Hassan, M. W., Khalid, A., & Bokhari, S. F. H. (2024) · Cureus · doi:10.7759/cureus.69129 · Cited by 10
“Obeticholic acid, a semisynthetic bile acid analog and potent FXR agonist has shown promising results in NASH trials [23].”
BackgroundWang, W., Li, L., Li, X., Chen, J., Wang, R., Yang, Q., Wang, C., & Meng, Q. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117308 · Cited by 9
Li, Z., Gu, Y., Yang, J., Wang, S., Li, S., Chen, P., Yao, R., Liu, F., Wang, Y., Wang, R., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1706401 · Cited by 7
Novel Therapies in Primary Biliary Cholangitis
Buchanan-Peart, K.-A., & Levy, C. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.013 · Cited by 7
Jamal, F., Elshaer, A., Alatout, M. H., Odeh, N. B., Youssef, A., Abo Abdullah, H., Elmasry, S., Shahin, T., Abdul Nabi, H., Worden, A. R., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13102335 · Cited by 6
“FXR, a nuclear bile acid receptor, plays a central role in regulating bile acid homeostasis and stimulates the secretion of gut-derived hormones, particularly fibroblast growth factor 19 [26,27].”
Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies
Curto, A., Iamello, R. G., Lynch, E. N., & Galli, A. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i30.109028 · Cited by 6
“These effects are mediated in part by the induction of fibroblast growth factor 19 and suppression of nuclear factor-kappa B-mediated inflammation[67-69].”
Abdeljawad, M. M., Hasan, M. T., Fareed, A., Abouelmagd, K., Saed, S. A. A., Ali, S., Keshk, M., Khan, M., Taha, N. A., & Taha, A. M. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103786 · Cited by 6
Exploring the potential of drug repurposing for liver diseases: A comprehensive study
Ali, F. E. M., Abdel‐Reheim, M. A., Hassanein, E. H. M., El‐Aziz, M. K. A., Althagafy, H. S., & Badran, K. S. A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122642 · Cited by 7
Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies—A Critical Overview
Kasztelan‐Szczerbińska, B., Rycyk, A., Szczerbińska, A., & Cichoż‐Lach, H. (2023) · Nutrients · doi:10.3390/nu15030760 · Cited by 6
“OCA, by activating FXR, stimulates intrinsic pathways leading to decreasing hepatic BA synthesis and uptake and increasing BA outflow from the liver.”
BackgroundInfluentialMa, P., Ou, H., Sun, Z., Lu, Y., Li, M., Xu, L., Yan, L., Zheng, J., & Ou, Y. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c08932 · Cited by 6
Wang, Y., Chen, Y., Cong, Y.-X., Wang, Y.-P., Liu, P., Du, Y.-P., Zhang, J., Wang, X.-C., Xu, T., Sinclair, A. J., et al. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110136 · Cited by 6
Wang, J., Tang, Q., Yuan, Z., Zhang, H., Miao, Y., Shen, W., Shen, W., Yu, Q., Zhang, L., & Jiang, Z. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111752 · Cited by 3
Li, X., Zhang, H., Li, C., Zheng, W., Wang, M., Wu, M., Yang, D., Hu, Y., Huo, D., Xu, Z., et al. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.905 · Cited by 3
“Exclusion criteria were: (1) history of long-time smoking or alcohol and/or drug abuse; (2) received any medication within 14 days prior to the initial dose of study drug or during the study; or (3) participated in a clinical trial of an investigational drug in the previous 3 months.”
BackgroundA Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor
Narayanan, A. K., Sudhindran, S., Balakrishnan, D., Gopalakrishnan, U. A., Malick, S., Valsan, A., Philips, C. A., & Watson, C. J. E. (2023) · Current Clinical Pharmacology · doi:10.2174/0127724328239536230919070001 · Cited by 3
Drug treatments to prevent first decompensation in cirrhosis
Kezer, C. A., Berzigotti, A., Fortune, B. E., & Simonetto, D. A. (2024) · Hepatology · doi:10.1097/hep.0000000000001117 · Cited by 4
Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis
Warsop, Z. I., Anand, N., Maliki, H. A., Souza, S. D., Kamyab, A. A., Hadad, A. A., & Alrubaiy, L. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14121133 · Cited by 4
“It ag-onises the farnesoid X receptor to reduce bile acid synthesis, liver inflammation, and fibrosis [45,46].”
The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism
Wang, X., Ning, C., Cheng, X., Wu, Z., Wu, D., Ding, X., Ju, C., Zhou, Z., Wan, L., Zhao, W., et al. (2024) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12506 · Cited by 3
“11 The development of OCA was predicated on the identification of chenodeoxycholic acid, a natural bile acid, as the most potent physiological ligand for the farnesoid X receptor (FXR).”
Ezz-Eldin, Y. M., Azouz, A. A., Khalaf, M. M., & Ewees, M. G. (2026) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2026.2638333 · Cited by 2
Yamaguchi, T., Shibata, K., Hasumi, K., & Nobe, K. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00771 · Cited by 2
“47) Selonsertib acts as an instigator of the p38/c-Jun N-terminal kinase (JNK) pathway and governs the process of hepatocyte apoptosis.”
Targeting Ischemia-reperfusion injury in liver transplant rejuvenation
Dery, K. J., Kaldas, F. M., & Kupiec‐Weglinski, J. W. (2025) · Transplantation Reports · doi:10.1016/j.tpr.2025.100176 · Cited by 2
Nagunuri, G. C. L., Katangoor, V., Surigilla, V., Sajja, E., Srinivasan, T. R., & Mathad, V. T. (2022) · Organic Process Research & Development · doi:10.1021/acs.oprd.2c00237 · Cited by 2
Li, Y., Tian, C., Song, X., Du, M., Zhang, G., & Liu, H. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s395114 · Cited by 2
“However, the side effect of pruritus seriously restricts its clinical application.(9,10) Therefore, the researches of discovering effective and safe drugs for cholestasis are still very important and urgent.”
BackgroundMorgado, J., Machado, I. F., Rolo, A. P., & Palmeira, C. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062599 · Cited by 1
“They showed improvements in steatosis and fibrosis despite frequently causing dose-dependent pruritus and atherogenic changes in LDL cholesterol levels [115].”
Romeo, M., Basile, C., Imperatore, A., Mozzi, G., Nardo, F. D., Napolitano, C., Vaia, P., Puorto, L. D., Indipendente, M., Dallio, M., et al. (2026) · Cells · doi:10.3390/cells15141292 · Cited by 2
“OCA, a semisynthetic FXR agonist, represented the first approved second-line pharmacological therapy for patients with PBC showing an inadequate response or intolerance to UDCA [141].”
Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients
McCain, J. D., Chascsa, D. M. H., & Lindor, K. D. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.1898370 · Cited by 1
“x receptor which plays a regulatory role in bile acid homeostasis [73].”
BackgroundBoslem, E., Riebe, S., Smeuninx, B., Egan, C. L., Tegegne, S., McLennan, E. D., Nobis, M., Mu, A., Nowell, C. J., Horadagoda, N. U., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4001943
Research Progress in the Treatment of Primary Biliary Cholangitis with Chinese and Western Medicine
陈, 坤. (2024) · Traditional Chinese Medicine · doi:10.12677/tcm.2024.132041
Li, S., Yang, M., Zhang, J.-Y., Liu, C., Bo-ping, W., Wu, Q., Tang, W.-Y., & Zeng, S. (2024) · Journal of Chromatography B · doi:10.1016/j.jchromb.2024.124296
Qi, F., Guo, B., Lu, H. J., Lei, Y., Liu, M., Yan, J., Liu, J., Liu, S., Li, S., Gu, Q., et al. (2025) · Cell Biochemistry and Function · doi:10.1002/cbf.70099
“In recent years, numerous new drugs for the treatment of NASH have emerged, such as obeticholic acid (an FXR agonist) [6, 7] and liraglutide (a GLP ‐ 1 agonist) [8, 9].”
Biliary Atresia and Neonatal Disorders of the Bile Ducts
Samyn, M., Hadžić, N., & Mieli‐Vergani, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11760-2.00070-7
Lavoie, A.-A., Thérien, A., Silva, A. J., Paré, E., Cieślak, A., Gagnon, W., Desjardins, C., Verreault, M., Trottier, J., Vohl, M., et al. (2025) · Biochemical Journal · doi:10.1042/bcj20253113
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741360
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26143803
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741375
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741366
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741381
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741372
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741378
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741384
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741387
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26143716
Metadata
- Authors
- Chapman, R. W., & Lynch, K. D.
- Affiliations
- University of Oxford (GB)
- Royal Adelaide Hospital (AU)
- Corresponding author
- Chapman, Roger W
- Venue
- British Medical Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03
- Volume
- 133
- Issue
- 1
- Pages
- 95-104
- ISSN
- 0007-1420 (ISSN-L)
- 1471-8391
- OpenAlex
- W3015589350
- Cited by
- 116
- References
- 25
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 34 · 2023: 17 · 2022: 16 · 2021: 12 · 2020: 3
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- British Medical Bulletin (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- obeticholic acid, farnesoid X receptor agonist, primary biliary cirrhosis, nonalcoholic steatohepatitis, bile acid analogues, ursodeoxycholic acid, FGF19, pruritus, serum alkaline phosphatase, liver fibrosis, HDL cholesterol, cardiovascular risk, drug costs, combination therapy
- MeSH terms
- Receptor, Farnesoid X-Activated, Chenodeoxycholic Acid, Gastrointestinal Agents, Humans, Liver Cirrhosis, Biliary, Treatment Outcome, Receptors, Cytoplasmic and Nuclear, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.